Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
about
Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cellsOne-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probesc-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlationCurrent approach to cutaneous mastocytosis in childhoodGermline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosisGenomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosisHotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivityTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthCharacterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRIEvolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.Mastocytosis.Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): an in silico analysis.Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.Clinical and biologic diversity of leukemias occurring in patients with mastocytosis.Mastocytosis: recent advances in defining the disease.Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.Cutaneous mastocytosis associated with a mixed germ cell tumour of the ovary: report of a case and review of the literature.A possible mechanism of mast cell proliferation in mastocytosis.Class III receptor tyrosine kinases: role in leukaemogenesis.Recent advances in the understanding of mastocytosis: the role of KIT mutations.Mastocytosis: state of the art.Receptor tyrosine kinase mutations in myeloid neoplasms.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma.Familial occurrence of systemic mast cell activation disease.Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.KIT mutations are common in testicular seminomas.Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.Diagnosis and treatment of systemic mastocytosis: state of the art.Biology of gastrointestinal stromal tumors: KIT mutations and beyond.Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Mastocytosis: pathology, genetics, and current options for therapy.Impaired function of bone marrow stromal cells in systemic mastocytosis.Clonality and molecular pathogenesis of mastocytosis.
P2860
Q24313261-90EE3FD2-99C9-4BDE-ADE2-85271610ED1BQ24685763-0BCE32DD-B244-40A5-AC2F-19BD141D1FD1Q24685927-6024115C-CDB7-473A-8C95-B9C52B38A091Q28073836-3B2AE77F-6D54-4A6A-89B7-4071CF3AA2D4Q28080034-9B8F3245-564D-4873-B7F8-9F161597C582Q28344714-224FB48C-ABB9-4E86-BBCA-0CB0C24DDF4BQ28541374-24F4D850-18D0-4193-B05E-050C674F2434Q28828739-C73AA20C-EC4C-4980-BB59-0AB470E760F1Q30428097-1C180BBD-D099-4AC5-B22A-20E3F630F672Q30914592-CE85369A-3CC8-4925-9F1D-776F0213B507Q33163541-244A9735-5545-4F9F-8EF3-75646DEB6F02Q33208353-C8438B1E-3820-4E18-AC73-26267911FC1CQ33238296-76CDE34E-8F6F-48A1-805D-B410634619A3Q33327689-08822135-082B-49E7-8368-62EF9A384501Q33537429-92911BD0-3710-4670-9692-ECE69C054DC2Q33753094-6721C2E9-3F55-43E5-9F30-7A2C5A6A6C7FQ33840864-352B3A9C-45D6-4928-BB6A-95B88CABD0B0Q34066643-C53DB3EC-C484-41F0-8B56-C632ADF272C3Q34216451-AD9CB631-69D9-4BC8-8E44-87C1BD855247Q34293285-7154D8BE-754D-458C-9097-B56A20CD82D7Q34352682-0A200F5D-1E4B-44CE-A6CE-0F537A1E5514Q34523898-94063A06-F27B-40FC-BF76-C537313DF38EQ34557003-ADBDDC0D-3C5B-49B1-99D7-6ECCC5CA0AF3Q34635424-ED13E936-BA31-4383-A308-0F99ADD777F0Q34641105-AEE8C1E1-D875-4310-B25F-7D60BAC80D26Q34655403-8BA95673-C7A9-4C64-A934-878A752BADC3Q34664111-67BF0D71-155D-4AB8-8A32-7C610A4F75CFQ34690237-6D677E09-664E-4861-8D4F-8E7D1B638605Q35010297-D2BA02B4-3C33-412C-9099-7AC80817D471Q35051746-B1FE4E6C-6D7B-4760-8210-0505754281EBQ35083255-37206292-F6CC-42D8-AAA8-11B4FA156D95Q35169575-B5EC82BC-7A98-4249-8232-1F78E349F08CQ35203889-D6786F03-97D5-430D-B07F-F187834F4444Q35740268-D111409A-BE4B-4DC7-83A2-845C20E89F8CQ35782893-AD9DC01C-FC07-49B3-B4FF-7C980E69A674Q35807869-D577CC31-F38A-4225-8DC3-55943EC17024Q35854970-44BDF571-9971-4856-BC4F-583324417739Q35994902-2F00BBCD-A0A3-4930-BA21-809066079B9AQ36020308-09B64992-DF81-4502-8235-A5AAE32FDE04Q36182758-43E2443D-1654-407C-9E89-4142AD239654
P2860
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Activating and dominant inacti ...... al forms of human mastocytosis
@ast
Activating and dominant inacti ...... al forms of human mastocytosis
@en
Activating and dominant inacti ...... al forms of human mastocytosis
@en-gb
Activating and dominant inacti ...... al forms of human mastocytosis
@nl
type
label
Activating and dominant inacti ...... al forms of human mastocytosis
@ast
Activating and dominant inacti ...... al forms of human mastocytosis
@en
Activating and dominant inacti ...... al forms of human mastocytosis
@en-gb
Activating and dominant inacti ...... al forms of human mastocytosis
@nl
prefLabel
Activating and dominant inacti ...... al forms of human mastocytosis
@ast
Activating and dominant inacti ...... al forms of human mastocytosis
@en
Activating and dominant inacti ...... al forms of human mastocytosis
@en-gb
Activating and dominant inacti ...... al forms of human mastocytosis
@nl
P2093
P2860
P3181
P356
P1476
Activating and dominant inacti ...... al forms of human mastocytosis
@en
P2093
B J Longley
D D Metcalfe
P2860
P304
P3181
P356
10.1073/PNAS.96.4.1609
P407
P577
1999-02-16T00:00:00Z